Literature DB >> 29933717

Molecular and point-of-care diagnostics for Ebola and new threats: National POCT policy and guidelines will stop epidemics.

Gerald J Kost1.   

Abstract

INTRODUCTION: US hospitals that admitted Ebola virus disease (EVD) patients mitigated risk by using point-or-care testing (POCT) for critical support in isolation units. Success proved unequivocally the need for POCT. Additionally, molecular diagnostics have been used to help stop new outbreaks, and even handheld diagnostic solutions are emerging. Areas covered: This update of 'Molecular detection and point-of-care testing in Ebola virus disease and other threats' [Expert Reviews 2015;15(10):1249-1255], assesses the impact of EVD epidemics, documents insights from recent reviews, summarizes evolving POC molecular technologies, presents General Accountability Office (GAO) recommendations, identifies the role of POC Coordinators, and casts a vision for national POCT policies and guidelines. Factual updating comprised summarizing EVD outbreaks including 2017-2018, analyzing reviews and evidence-based publications since the 2014-2016 epidemic, and tabulating published technical and molecular diagnostics. New graphics illustrate POC error mitigation/risk reduction, a framework for national POCT policy and guidelines, modular adaptations for country-specific solutions, and a logic diagram for future progress embedding artificial intelligence. Expert commentary: The USA is still not prepared for highly infectious diseases. Key is lack of community rapid response and resilience, which must be enhanced not via mechanisms distant, but instead by molecular diagnostics directly at critical points of need.

Entities:  

Keywords:  Molecular and Point-of-Care Diagnostics, Ebola and New Threats, National POCT Policy and Guidelines, Epidemics

Mesh:

Year:  2018        PMID: 29933717     DOI: 10.1080/14737159.2018.1491793

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  6 in total

1.  Analytical Performance Evaluation of Three Commercial Rapid Nucleic Acid Assays for SARS-CoV-2.

Authors:  Jie Yi; Xiao Han; Ziyi Wang; Yu Chen; Yingchun Xu; Jie Wu
Journal:  Infect Drug Resist       Date:  2021-08-14       Impact factor: 4.003

2.  The Coronavirus Disease 2019 Spatial Care Path: Home, Community, and Emergency Diagnostic Portals.

Authors:  Gerald J Kost
Journal:  Diagnostics (Basel)       Date:  2022-05-12

Review 3.  Geospatial Science and Point-of-Care Testing: Creating Solutions for Population Access, Emergencies, Outbreaks, and Disasters.

Authors:  Gerald J Kost
Journal:  Front Public Health       Date:  2019-11-26

4.  Public Health Education Should Include Point-of-Care Testing: Lessons Learned from the Covid-19 Pandemic.

Authors:  Gerald J Kost
Journal:  EJIFCC       Date:  2021-10-18

5.  A rapid and label-free platform for virus capture and identification from clinical samples.

Authors:  Yin-Ting Yeh; Kristen Gulino; YuHe Zhang; Aswathy Sabestien; Tsui-Wen Chou; Bin Zhou; Zhong Lin; Istvan Albert; Huaguang Lu; Venkataraman Swaminathan; Elodie Ghedin; Mauricio Terrones
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-27       Impact factor: 11.205

6.  A flexible format LAMP assay for rapid detection of Ebola virus.

Authors:  Laura C Bonney; Robert J Watson; Gillian S Slack; Andrew Bosworth; Nadina I Vasileva Wand; Roger Hewson
Journal:  PLoS Negl Trop Dis       Date:  2020-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.